Answers are grounded in this paper and cite their sources.
Review uncovers novel human dihydrofolate reductase inhibitors and chemical strategies in cancer chemotherapy, highlighting pathways for selective drug discovery.
Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry community to develop novel and selective human DHFR inhibitors, thus leading to a new generation of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery are also provided, in order to thoroughly delineate the current landscape for medicinal chemists interested in furthering this study in the anticancer field.
No takes yet. Share an insight, caveat, or question.
Raimondi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: